جستجوی استاد راهنمای دانشگاهی

• Gynecologic Oncology
• Women’s Health
• Cancer Treatment
• +۵ مورد دیگر

Dr. Laila Ingrid Muderspach is a Clinical Professor of Obstetrics & Gynecology at the University of Southern California (USC) on a part-time basis. She specializes in the diagnosis and treatment of gynecologic malignancies, emphasizing patient-centered care that addresses physical, emotional, and socioeconomic needs. Her clinical expertise spans surgical and medical interventions for cancers of the female reproductive system, with a focus on improving outcomes through advanced techniques like Enhanced Recovery After Surgery (ERAS) pathways and sentinel lymph node biopsies. Dr. Muderspach’s research spans epidemiological trends in gynecologic cancers, including adolescent and young adult (AYA) populations, and the optimization of surgical and chemotherapy protocols. She has contributed to pivotal studies on endometrial and cervical cancer staging, palliative care utilization, and the management of complications in vulvar cancer surgery. Her work also addresses healthcare disparities, such as accessibility to obstetric care and adherence to cancer treatment in underserved communities. Education: Medical degree from an unspecified institution, with training at USC and UCLA. Awards: Over 30 awards including Best Doctors recognition (2009–2014), National Faculty Award (2007), and multiple teaching accolades. Labs/Teams: Active in multidisciplinary gynecologic oncology teams at LAC+USC Medical Center, focusing on surgical innovation and patient safety. Her publications (over 150 listed) reflect a commitment to translational research, including clinical trials for novel therapies like eribulin for cervical cancer and investigations into HPV vaccine impact on cervical lesions.

Anthony A Gattiمشاهده پروفایل

پژوهشگر ارشد

• Biomechanics
• Medical Imaging
• Machine Learning
• +۷ مورد دیگر

Anthony A Gatti is a Postdoctoral Scholar at Stanford University's Wu Tsai Human Performance Alliance and School of Medicine. His research integrates biomechanics , medical imaging , and machine learning to advance musculoskeletal health diagnostics, particularly focusing on knee osteoarthritis and exercise physiology. Education : Ph.D. in Rehabilitation Science (McMaster University, 2021), M.Sc. in Rehabilitation Science (McMaster University, 2015), B.Sc. in Kinesiology (McMaster University, 2013) His research develops automated tools for quantifying knee anatomy and integrating anatomical data with biomechanical models . These methods analyze acute responses to exercise and long-term joint degeneration, leveraging MRI , deep learning , and statistical shape modeling . Recent publications emphasize AI-driven segmentation , exercise-induced cartilage changes , and biomechanical simulations , spanning journals like Magnetic Resonance in Medicine and Arthritis & Rheumatology . Trends include machine learning validation for clinical predictions and open-source tool development for musculoskeletal analysis. Scientific Awards : CIHR Postdoctoral Fellowship (top 1%), Mitacs Accelerate Entrepreneur, Forge Student Start-Up Competition Winner, multiple scholarships from McMaster University He founded NeuralSeg , a company commercializing deep learning-based MRI segmentation technology. Collaborations include Stanford's Digital Athlete Moonshot Project with advisors like Scott Delp and Garry Gold.

Andrew T Arndtمشاهده پروفایل

استادیار بالینی

• Thoracic Surgery
• Lung Cancer
• Chest Wall Tumors
• +۳ مورد دیگر

Andrew T Arndt, MD is a Clinical Assistant Professor in the Department of Surgery specializing in Thoracic Surgery at Northwestern University's Feinberg School of Medicine. Board certified by the American Board of Thoracic Surgery, he maintains clinical practice at Northwestern Medicine Central DuPage Hospital and holds active memberships in the Society of Thoracic Surgeons (2023-present) and American Board of Thoracic Surgery (2022-present). His research concentrates on advancing thoracic surgical oncology through investigations into lung cancer resection outcomes, chest wall tumor management, minimally invasive techniques, and pneumothorax recurrence factors. Current work emphasizes evidence-based risk stratification and surgical innovation to improve patient outcomes in complex thoracic pathologies. Recent publications demonstrate consistent focus on surgical registry analysis (2021), consensus development for thoracoscopic training (2021), systematic reviews of rare chest wall malignancies (2023), and identification of lifestyle-related recurrence risks (2021). This trajectory highlights growing contributions to thoracic surgical guidelines and evidence-based practice standards. Dr. Arndt serves as a consultant for Intuitive Surgical, Inc. (2024 disclosures) while maintaining active clinical and academic roles. No formal advisees or research grants are listed in current profile materials. Within Northwestern's Department of Surgery, he contributes to the Thoracic Surgery division's clinical and research missions, particularly in advancing minimally invasive approaches and multidisciplinary management of complex thoracic conditions through collaborative registry studies and consensus initiatives.

Ozan Seymen Sezenمشاهده پروفایل

دانشیار

• Rhinoplasty
• Facial Aesthetic and Plastic Surgery
• Snoring and Sleep Apnea Surgery
• +۳ مورد دیگر

Prof. Dr. Ozan Seymen Sezen is an Associate Professor specializing in Ear, Nose, and Throat (ENT) Diseases with dual affiliations at Istanbul Okan University Hospital since 2019 and Kartal Dr. Lütfi Kırdar Training and Research Hospital since 2001. He earned his medical degree from Istanbul University Cerrahpaşa Faculty of Medicine in 1993, completed his ENT specialization in 2000 after training at the University of Michigan Medical School, and achieved associate professorship status in 2012. His educational background includes: Master's Degree from Istanbul University Cerrahpaşa Faculty of Medicine Medical Specialization in ENT at SB Dr. Lütfi Kırdar Kartal Training and Research Hospital Associate Professorship in ENT at the same institution Prof. Sezen has developed specialized expertise in facial aesthetic and plastic surgery, particularly rhinoplasty, with additional focus on snoring and sleep apnea surgery, ear diseases and surgery, and sinus diseases and surgery. His clinical practice significantly exceeds typical volumes in endoscopic sinus surgery, sleep apnea procedures, rhinoplasty, and head and neck cancer surgeries. His research spans surgical innovations, pathological studies, and interdisciplinary connections between ENT and other medical specialties. His publication record demonstrates consistent scholarly contributions over two decades, with recent emphasis on sleep apnea treatment techniques, rhinoplasty innovations, and physiological impacts of ENT interventions. The research shows strong translational focus from laboratory studies to clinical applications. Key professional recognitions include: European Otorhinolaryngology Head and Neck Surgery Certificate of Competency (2012) Fellow of the European Board of Otorhinolaryngology Head and Neck Surgery As an educator, Prof. Sezen has continuously provided scientific, practical, and surgical training to resident doctors and medical students throughout his career. He has participated in over 20 national and international courses and congresses between 2010-2018, with specialized focus on facial plastic surgery techniques. His research collaborations span multiple institutions with emphasis on advancing ENT surgical practices through evidence-based approaches. Professional affiliations demonstrate his commitment to interdisciplinary collaboration, including membership in the Turkish Otorhinolaryngology Head and Neck Surgery Association, Facial Plastic Surgery Association, Turkish Sleep Research Association, European Academy of Facial Plastic Surgery, and American Academy of Cosmetic Surgery.

Knut Håkon Holeمشاهده پروفایل

دانشیار

• Radiology
• Oncology
• Medical Imaging
• +۴ مورد دیگر

Knut Håkon Hole is an Associate Professor at the University of Oslo's Department of Radiology and Nuclear Medicine. His research focuses on diagnostic imaging applications in oncology, particularly in prostate and rectal cancers. He specializes in MRI, PET, and radiogenomics techniques to assess tumor biology, treatment response, and recurrence. Expertise: Prostate cancer imaging, neoadjuvant therapy response, tumor hypoxia, and imaging biomarkers Key affiliations: Oslo University Hospital (Rikshospitalet), Radium Hospital Research interests include: Developing MRI and PET protocols for cancer staging and recurrence detection Integrating imaging with genomic data (radiogenomics) Optimizing therapeutic approaches using imaging biomarkers Recent work highlights: Prostate cancer radiogenomics and hypoxia biomarkers (2024) MRI/PET comparisons for tumor localization (2021-2023) Neoadjuvant therapy response assessment in rectal and breast cancers (2020-2023) Publications span over 50 peer-reviewed articles with a focus on translational imaging research. Collaborates extensively with oncology and urology teams.

Andrew Godwinمشاهده پروفایل

استاد

• Molecular Oncology
• Precision Medicine
• Biomarker Discovery
• +۳ مورد دیگر

Andrew Godwin is a Professor at the University of Kansas Medical Center , where he serves as the Chancellor’s Distinguished Chair in Biomedical Sciences and Director of Molecular Oncology in the Department of Pathology and Laboratory Medicine. He is also the Deputy Director of the NCI-designated University of Kansas Cancer Center and the Founding Director of the Kansas Institute for Precision Medicine and Biospecimen Shared Resource . Dr. Godwin is a leader in translational research and precision medicine , with a focus on molecular oncology , biomarker discovery , and genomic diagnostics . His work bridges basic and clinical science to improve cancer patient care, particularly in ovarian cancer , Ewing sarcoma , and breast cancer . He has contributed over 230 ovarian cancer-related publications and pioneered studies linking the PI3K/AKT pathway to cancer treatment targets. His research program encompasses liquid biopsies using extracellular vesicles , molecular therapeutics , companion diagnostics , and clinical trial validation . He leads the Biomarker Discovery Laboratory and has secured over $250M in extramural funding , including a $11.4M NIH grant for precision medicine initiatives. His team has developed CELLSEARCH® , the first FDA-cleared test for circulating tumor cells. Notable awards include the Dolph C. Simons, Sr. Higuchi Award (2020), Outstanding Mentorship in Pathology Award (2024), and multiple mentoring accolades from KU. He has mentored over 150 trainees across career stages and leads a multidisciplinary lab with expertise in genomics , proteomics , and bioengineering . Academic Roles: Chancellor’s Distinguished Chair in Biomedical Sciences Director, Molecular Oncology, Pathology and Laboratory Medicine Deputy Director, KU Cancer Center Founding Director, Kansas Institute for Precision Medicine Adjunct Professor, Bioengineering Program, University of Kansas Scientific Awards: KUMC Achievement Award for mentoring postdocs (2014) Chancellor’s Club Award for Research (2018) Dolph C. Simons, Sr. Higuchi Award (2020) KU Excellence in Mentoring Award (2021) Outstanding Mentorship in Pathology (2024) Key Research Themes: Extracellular vesicles as liquid biopsy tools Molecular mechanisms of sarcoma and breast cancer Genomic diagnostics and precision oncology Clinical trial biomarker validation Biospecimen repository leadership

• Cancer Staging
• Outcomes Research
• Surgical Oncology
• +۵ مورد دیگر

Elliot A. Asare, MD, MS, CMQ, FACS serves as Assistant Professor in the Section of Surgical Oncology within the Division of General Surgery at the University of Utah. He specializes in cutaneous malignancies and sarcomas of the retroperitoneum and soft tissues, practicing clinically at both Huntsman Cancer Institute and Intermountain Healthcare Center in Murray. His educational trajectory includes: Phi Beta Kappa graduate with B.S. in Biology and Chemistry (double major) from Randolph-Macon College M.D. from Howard University College of Medicine (Alpha Omega Alpha inductee) General Surgery residency at Medical College of Wisconsin Affiliated Hospitals M.S. in Health Services and Outcomes Research from Northwestern University Complex General Surgical Oncology fellowship at University of Texas MD Anderson Cancer Center Dr. Asare's research program centers on cancer staging methodology, data quality enhancement, prognostication frameworks, and outcomes research with emphasis on health disparities. His work integrates large-scale database analyses (SEER, National Cancer Data Base) to refine AJCC staging systems while addressing inequities in melanoma and sarcoma care across elderly, minority, and rural populations. Recent investigations explore sentinel lymph node biopsy efficacy in aging patients and viral infection impacts on melanoma mortality. His 2023-2025 publications reveal three dominant themes: (1) AJCC Version 9 implementation across multiple cancer types (anal, appendiceal, neuroendocrine), (2) persistent disparities in skin cancer outcomes linked to demographic and geographic factors, and (3) telehealth applications for expanding surgical oncology access. These studies consistently leverage national datasets to validate staging systems while identifying structural barriers to equitable care. Professional recognition includes: Phi Beta Kappa honor society membership Alpha Omega Alpha Medical Honor Society induction Fellowship in the American College of Surgeons (FACS) Dr. Asare actively contributes to surgical oncology education through The SCORE Portal as item writer for soft tissue neoplasm assessments and via publications on medical education frameworks. His institutional affiliations with Huntsman Cancer Institute and Intermountain Healthcare provide platforms for multidisciplinary sarcoma and melanoma management, where he integrates evidence-based staging protocols with patient-centered surgical approaches as evidenced by consistently high patient satisfaction scores (4.9/5 from 166 reviews).

Georgia Marie Beasleyمشاهده پروفایل

دانشیار

• Melanoma Research
• Immunotherapy
• Surgical Oncology
• +۳ مورد دیگر

Georgia Marie Beasley is an Associate Professor of Surgery and Medicine at Duke University School of Medicine, with active faculty membership in the Duke Cancer Institute. Her clinical practice focuses on surgical oncology for melanoma treatment, while her research bridges innate immunity and anti-tumor responses. She earned her MD (2008) and MHS in clinical research (2010) from Duke, followed by general surgery residency (2008-2015) and a surgical oncology fellowship at Ohio State University (2015-2017). Education: Duke University School of Medicine (MD, 2008) Duke University (MHS, 2012) Duke University (B.A., 2001) Dr. Beasley's research centers on immunologic aspects of melanoma, particularly oncolytic viral therapy and innate immune mechanisms in tumor response. She leads over 10 therapeutic clinical trials for melanoma, including innovative intratumoral treatments, and has authored more than 100 publications on these topics. Her work explores the intersection of tumor microenvironment dynamics, immune status measurement, and microbiome interactions in cancer progression. Recent publications highlight her focus on circulating tumor DNA applications (2025), GLI2 signaling in immune evasion (2025), and national trends in pediatric stage III melanoma management (2025). These reflect broader research priorities in melanoma staging accuracy, immune-based therapies, and translational oncology. Scientific Awards: Society of Surgical Oncology Young Investigator Award NIH K08 Mentored Physician Scientist Award Melanoma Research Alliance Grant Duke Medical School Alpha Omega Alpha Honor American Society for Clinical Investigation Young Physician-Scientist Award Dr. Beasley secures substantial funding through grants including a 2024-2029 National Cancer Institute award for Duke Research Training in Surgical Oncology, a 2024-2026 NIH grant for older adult melanoma decision-making, and a 2023-2026 Department of Defense grant measuring immune status to prevent recurrence. She also collaborates on training programs at the intersection of cancer immunology and microbiome bioinformatics.

• Molecular Imaging
• Positron Emission Tomography (PET)
• Cancer
• +۴ مورد دیگر

Professor Andreas Kjær (MD, PhD, DMSc) serves as Head of the Cluster for Molecular Imaging (CMI) at the Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen. He is also Chief Physician at Rigshospitalet and co-founder of Minerva Imaging, a CRO established in 2011. University of Copenhagen Department of Biomedical Sciences Cluster for Molecular Imaging Rigshospitalet His research focuses on translational molecular imaging with PET/PET-MRI and targeted radionuclide therapies (theranostics) for precision medicine in cancer, cardiovascular, and inflammatory diseases. CMI bridges basic research to clinical implementation, leveraging interdisciplinary expertise in physics, chemistry, biology, and medicine to develop imaging agents and therapies. Recent publications highlight advancements in theranostics , PET/CT , hyperpolarized MRI , and radiopharmaceutical development . Collaborations span oncology, cardiology, and nuclear medicine, with clinical trials in neuroendocrine tumors and metabolic imaging. Current affiliations include University of Copenhagen (Professor, Department of Biomedical Sciences) Rigshospitalet (Chief Physician)

Mohan Sunthaمشاهده پروفایل

استاد

• Radiation Oncology
• Head and Neck Cancer
• Esophageal Carcinoma
• +۳ مورد دیگر

Mohan Suntha, MD, MBA, serves as Professor of Radiation Oncology at the University of Maryland School of Medicine and holds a secondary appointment in Otorhinolaryngology-Head & Neck Surgery. He concurrently serves as President and Chief Executive Officer of the University of Maryland Medical System (UMMS), a role he assumed in 2019 after previously leading the University of Maryland Medical Center since 2016. His educational background includes: BA in Biology from Brown University (1986) MD from Jefferson Medical College (1990) Residency in Radiation Oncology at University of Maryland School of Medicine (1994) Clinical Oncology Fellowship in Head & Neck Malignancies (1994-1995) MBA from The Wharton School (2009) Dr. Suntha's research focuses on carcinomas of the head, neck, and esophagus, with emphasis on optimizing combined modality approaches through investigator-initiated clinical trials. His work investigates concurrent chemoradiation protocols, neoadjuvant strategies, and surgical integration to improve therapeutic outcomes. Current investigations include tumor volume prognostic factors, molecular imaging applications, and quality indicators for surgical oncology procedures. His publications demonstrate consistent focus on head and neck cancer disparities, esophageal carcinoma management, and quality metrics in radiation oncology. Key trends include translational research connecting surgical pathology metrics with oncologic outcomes, prognostic biomarker identification, and health equity analysis in cancer care delivery. Award highlights include: Five-time 'Top Doctor' in Radiation Oncology by Baltimore Magazine (2007-2016) 2022 Influential Marylander Honoree in Healthcare by Maryland Daily Record Administratively, Dr. Suntha has held progressive leadership roles including Vice Chair of Radiation Oncology, Associate Director of Clinical Affairs at UMGCCC, Vice President for System Program Development at UMMS, and CEO of St. Joseph Medical Center. His current UMMS presidency encompasses oversight of Shock Trauma Center, Children's Hospital, and Greenebaum Comprehensive Cancer Center. While maintaining active clinical faculty status, his executive responsibilities focus on system-wide strategic development and healthcare delivery innovation.

• Radiation Oncology
• Cutaneous Lymphoma
• Breast Cancer
• +۵ مورد دیگر

Lynn D. Wilson, MD, MPH, FASTRO serves as Professor of Therapeutic Radiology and Dermatology at Yale School of Medicine, where he holds multiple leadership positions including Executive Vice Chairman of Therapeutic Radiology, Deputy Chief Medical Officer for Radiation Oncology Services at Yale Cancer Center and Smilow Cancer Hospital, Director of Clinical Affairs, and Associate Director of the Residency Training Program. As a board-certified radiation oncologist, he specializes in treating cutaneous lymphoma and breast cancer patients at Smilow Cancer Hospital at Yale New Haven. Dr. Wilson's research program focuses on outcomes and treatment-related factors for patients with cutaneous lymphoma, lung and breast cancers. His work has revealed significant disparities in clinical outcomes for cutaneous lymphoma based on race, prompting further investigation into potential causes and solutions. He has developed expertise in specialized techniques including total skin electron beam therapy, which Yale has established as a major national program with international recognition. His laboratory work spans radiation biology, treatment optimization, and health services research related to radiation oncology practice patterns. Analysis of Dr. Wilson's recent publications (2017-2021) reveals three major research themes: (1) cutaneous lymphoma treatment outcomes and health disparities, (2) breast cancer radiotherapy techniques (particularly deep inspiration breath hold and proton therapy), and (3) radiation oncology workforce and education patterns. His work consistently appears in high-impact journals including the International Journal of Radiation Oncology • Biology • Physics, Journal of Investigative Dermatology, and Journal of the National Comprehensive Cancer Network. America's Top Doctors for Cancer (2005-2018) America's Top Doctors (2007-2018) ASTRO Annual Meeting and Program Scientific Committee Chairman (2014) Top Doctors: New York Metro Area (2014) New York Magazine Best Doctors (2014) Dr. Wilson serves on the board of trustees for the American Board of Radiology and is a member of the American Society for Radiation Oncology board of directors. His leadership extends to chairing the Department of Therapeutic Radiology Quality Improvement Committee and serving on Yale Medicine's Operations Committee and Practice Operations and Standards Committee. He has mentored numerous residents and fellows through Yale's Radiation Oncology Residency Program and SRS/SBRT Fellowship program, with research collaborations spanning multiple departments including Dermatology, Medical Physics, and Radiobiology. Yale's Total Skin Electron Beam Therapy program, which Dr. Wilson leads, represents a major national resource for cutaneous lymphoma patients, combining clinical expertise with ongoing research to advance treatment approaches for this rare condition. His work bridges clinical care, research innovation, and educational leadership within the radiation oncology field.

• Breast Cancer
• Surgical Oncology
• DCIS Management
• +۳ مورد دیگر

Kelly C. Hewitt, MD, FACS, serves as a Clinical Associate Professor in the Department of Surgery at the University of Utah School of Medicine and practices as a breast surgical oncologist at University of Utah Health and Huntsman Cancer Institute. Her clinical expertise encompasses surgical management of malignant and benign breast diseases, with specialized focus on ductal carcinoma in situ (DCIS). Dr. Hewitt's educational background includes: B.A. in Biology from Johns Hopkins University M.D. from Georgetown University School of Medicine General Surgery Residency at the University of Utah School of Medicine Breast Surgical Oncology Fellowship at the University of California, San Francisco School of Medicine Her research centers on minimizing overdiagnosis and overtreatment of DCIS through active surveillance strategies and identifying optimal surgical candidates. She actively investigates clinical trials for early-stage breast cancer and works to enhance healthcare access across the Mountain West region. Dr. Hewitt emphasizes personalized care, collaborating with patients to align surgical plans with personal goals while ensuring disease management efficacy. Analysis of her 2020-2024 publications reveals dominant themes in DCIS management, axillary lymph node assessment, and surgical innovation. Key trends include superparamagnetic iron oxide (SPIO) mapping techniques, mastectomy recurrence patterns, and evidence-based approaches to reduce overtreatment. Her work bridges clinical practice with surgical oncology research to optimize patient outcomes. Professional Recognition: Fellow of the American College of Surgeons (FACS) As national co-principal investigator for the DCIS:RECAST clinical trial and contributor to the I-SPY2 trial network, Dr. Hewitt leads grant-funded research addressing critical gaps in breast cancer care. She mentors surgical trainees in breast oncology while navigating complex patient cases through multidisciplinary collaboration. Within Huntsman Cancer Institute's breast oncology program, Dr. Hewitt collaborates with national consortia to advance surgical techniques and patient-centered care models. Her leadership in Mountain West healthcare access initiatives demonstrates commitment to equitable cancer treatment delivery.

• Gastrointestinal Oncology
• Clinical Trials
• Pharmacogenomics
• +۶ مورد دیگر

Syma Iqbal, MD, is an Associate Professor of Clinical Medicine at the University of Southern California's Keck School of Medicine and Norris Comprehensive Cancer Center. She holds leadership roles as Medical Director for Inpatient Services at Norris Cancer Hospital, Medical Director of Ambulatory Services/Infusion Center, and Associate Cancer Physician in Chief. Dr. Iqbal chairs the Norris Clinical Investigations Committee and is a national thought leader in systemic therapy for esophageal and gastric cancers, including roles as co-Chair of the Southwest Oncology Group Esophago-Gastric Committee and Chair of the National Cancer Institute’s Esophago-Gastric Task Force. Dr. Iqbal graduated from the Keck School of Medicine of USC in 1995 and completed a Hematology and Oncology Fellowship in 2001. Her research focuses on clinical trials for gastrointestinal malignancies, pharmacogenomics in colorectal cancer, and molecular markers for treatment response and survival. Key publications highlight anti-HER2 therapies, PD-1 inhibitors, and genomic profiling in oncology. Her clinical trials span phase I-III studies in gastric, esophageal, colorectal, and pancreatic cancers, emphasizing drug combinations, resistance mechanisms, and biomarker-driven approaches. While no scientific awards are explicitly mentioned, her work has shaped national guidelines through leadership in cancer research consortia.

Wolfgang Weberمشاهده پروفایل

استاد

• Molecular Imaging
• Targeted Radionuclide Therapy
• Theranostics
• +۳ مورد دیگر

Prof. Wolfgang Weber is a Professor and Director of the Department of Nuclear Medicine at the Klinikum rechts der Isar, Technical University of Munich (TUM). His academic career includes roles such as Associate Professor at UCLA (2003–2007) and Chair of Nuclear Medicine at Albert Ludwig University of Freiburg (2007–2013). He specializes in molecular imaging and targeted radionuclide therapy, with a focus on cancer theranostics. His research addresses precision oncology through advanced imaging techniques for diagnosis and treatment monitoring. Education: Doctorate in Medicine from TUM (1995). Key prior appointments include Director of the Molecular Imaging and Therapy Service at Memorial Sloan Kettering Cancer Center (2013–2017) and Professor at Weill-Cornell Medical College. His work spans prostate cancer imaging, neuroendocrine tumors, and radiopharmaceutical development. Research interests emphasize integrating imaging modalities like PET/CT and SPECT for cancer staging, therapy response prediction, and novel radiotracer development. Notable contributions include PSMA-ligand PET imaging for prostate cancer recurrence detection and PARP inhibitor engagement studies in lung cancer. Publications highlight innovations in theranostic agents, such as 18F-rhPSMA-7 and Ga-68-based tracers. His work frequently addresses clinical trial validation of imaging biomarkers and dosimetry safety in radiolabeled therapies.

Robert E. Reiterمشاهده پروفایل

استاد

• Prostate cancer
• Biomarkers
• Prostate Imaging
• +۴ مورد دیگر

Dr. Robert E. Reiter is the Bing Professor of Urologic Oncology at the University of California, Los Angeles (UCLA), where he serves as Chief of the Division of Urologic Oncology and Director of UCLA's prostate cancer program. He is also Director of Urologic Research and Co-Director of the Genitourinary Oncology Program in UCLA's Jonsson Comprehensive Cancer Center. With over 2,500 robotic prostatectomies performed, Dr. Reiter is an internationally recognized expert in prostate cancer management and research. Dr. Reiter received his MD from Stanford University School of Medicine in 1988 and completed his MBA from UCLA Anderson School of Management. His urologic training was completed at Stanford and Baylor College of Medicine, followed by fellowship training in urological cancer at the National Cancer Institute. He is board certified in Urology by the American Board of Urology since 1998. Dr. Reiter's research focuses on prostate cancer biomarkers, imaging, and molecular mechanisms. He was among the first to integrate functional MRI and PSMA PET imaging into prostate cancer diagnosis and surgical management. His laboratory discovered the prostate stem cell antigen and developed antibodies targeting this protein, leading to novel imaging and therapeutic approaches. He has particular interest in multidisciplinary management of high-risk prostate cancer, incorporating genomics and precision medicine into treatment plans. Dr. Reiter's extensive publication record demonstrates leadership in prostate cancer imaging standardization (PROMISE framework), genomic characterization of advanced disease, and clinical guideline development through the NCCN. His work spans molecular biology, imaging technology, clinical trials, and evidence-based treatment protocols, with a clear trajectory toward precision oncology approaches for prostate cancer patients. Outstanding Achievement Award by the Urologic Oncology branch of the National Cancer Institute Super Doctors® Southern California (2024, 2025) Newsweek's America's Best Prostate Cancer Oncologists (2024) Top Doctors, Los Angeles Magazine (2019, 2021) Fellow of the American Society for Clinical Investigation Young Investigator Award of the Society for Urologic Oncology Dr. Reiter has led UCLA's $12 million SPORE grant for over 15 years, supporting translation of laboratory discoveries into clinical advances for prostate cancer. His research has contributed to drugs like enzalutamide and apalutamide, and imaging tools like PSMA PET. He has authored more than 250 papers and serves as a mentor to numerous researchers and clinicians in urologic oncology. His clinical trials focus on novel therapies for hormone-sensitive prostate cancer and advanced disease management. As Director of the Prostate Cancer Program and Co-Director of the Genitourinary Oncology Program, Dr. Reiter leads multidisciplinary teams integrating expertise from radiation oncology, medical oncology, nuclear medicine, and basic science to provide comprehensive care for prostate cancer patients. His research laboratory focuses on prostate stem cell antigen and related therapeutic approaches, with several novel imaging and treatment strategies currently in clinical trials.